Date: 2014-05-06
Type of information: Collaboration agreement
Compound: small molecule inhibitors against sodium coupled citrate transporter NaCT to treat metabolic diseases
Company: Evotec (Germany) Eternygen (Germany)
Therapeutic area: Metabolic diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On May 6, 2014, Evotec and Eternygen have announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec’s technology platform and broad expertise in drug discovery and pre-clinical development. Eternygen is working on the sodium coupled citrate transporter NaCT, a novel target which is a key regulator of energy metabolism involved in the pathogenesis of fatty liver, diabetes and obesity. Under the terms of the agreement, Evotec will use its best-in-class drug discovery platform to discover and develop a suitable clinical candidate. NaCT, also known as PMCT or SLC13A5, is a sodium coupled citrate transporter which is predominantly expressed in liver cells and the mammalian homolog of the INDY (“I am not dead yet”) gene in Drosophila. In mouse studies it was shown that NaCT knock out protects from adiposity and insulin resistance induced by aging and high-fat diet. Therefore NaCT is an attractive therapeutic target for the treatment of non-alcoholic fatty liver disease, obesity, and type 2 diabetes by influencing the mammalian energy metabolism.
Financial terms:
Latest news:
